PHAR vs DNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 11, 2026
PHAR
22.7
AI Score
VS
DNA Wins
DNA
48.2
AI Score
Investment Advisor Scores
DNA
48score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | PHAR | DNA | Winner |
|---|
Relative Price Performance (Last 90 Days)
PHAR 1M: +41.9%
· 3M: +8.5%
DNA 1M: -12.8%
· 3M: +41.6%
Current Technical Phase
PHAR
NeutralHold
Mixed signals - no dominant trend phase, RSI 73
DNA
NeutralHold
Mixed signals - no dominant trend phase, RSI 47
Fundamentals Snapshot
| Metric | PHAR | DNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 74.4 | -3.5 |
| Trailing P/E | 41.3 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.2% | -0.1% |
| Gross Margin | 0.9% | 0.7% |
| Operating Margin | 0.3% | -1.6% |
| EPS | 0.32 | -4.24 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, DNA is currently the stronger investment candidate based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.